 | • レポートコード：MRC2303G041 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療機器 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の心臓バイオマーカー市場規模が、予測期間中（2022年-2027年）CAGR 8.5％で増加すると推測されています。本書では、心臓バイオマーカーの世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（クレアチンキナーゼ、トロポニン、ミオグロビン、虚血変性アルブミン、その他）分析、用途別（ 鬱血性心不全、急性冠症候群、心筋梗塞、アテローム性動脈硬化症、その他）分析、用途別（POCT、実験室内試験）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Abbott Laboratories、Becton, Dickinson, and Company、BioMerieux、Bio-Rad Laboratories Inc.などが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の心臓バイオマーカー市場規模：種類別 - クレアチンキナーゼの市場規模 - トロポニンの市場規模 - ミオグロビンの市場規模 - 虚血変性アルブミンの市場規模 - その他心臓バイオマーカーの市場規模 ・世界の心臓バイオマーカー市場規模：用途別 - 鬱血性心不全における市場規模 - 急性冠症候群における市場規模 - 心筋梗塞における市場規模 - アテローム性動脈硬化症における市場規模 - その他用途における市場規模 ・世界の心臓バイオマーカー市場規模：用途別 - POCTにおける市場規模 - 実験室内試験における市場規模 ・世界の心臓バイオマーカー市場規模：地域別 - 北米の心臓バイオマーカー市場規模 アメリカの心臓バイオマーカー市場規模 カナダの心臓バイオマーカー市場規模 メキシコの心臓バイオマーカー市場規模 … - ヨーロッパの心臓バイオマーカー市場規模 ドイツの心臓バイオマーカー市場規模 イギリスの心臓バイオマーカー市場規模 フランスの心臓バイオマーカー市場規模 … - アジア太平洋の心臓バイオマーカー市場規模 中国の心臓バイオマーカー市場規模 日本の心臓バイオマーカー市場規模 インドの心臓バイオマーカー市場規模 … - 南米/中東の心臓バイオマーカー市場規模 ブラジルの心臓バイオマーカー市場規模 アルゼンチンの心臓バイオマーカー市場規模 サウジアラビアの心臓バイオマーカー市場規模 ・競争状況 ・市場機会・将来動向 |
The cardiac biomarkers market is poised to register a CAGR of 8.5% during the forecast period (2022-2027).
The market was significantly impacted by the COVID-19 pandemic. According to a study titled “Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us,” published in Current Problems in Cardiology (October 2021), in the majority of the complex cases of COVID-19, cardiac injury biomarkers were elevated. This elevation is inversely correlated with the worst outcome. A more reliable tool for case fatalities and outcomes is provided by the evaluation of cardiac biomarkers in combination with markers of other organ damage. However, as per the study titled “Cardiovascular Biomarkers in Patients with COVID-19,” biomarkers measuring cardiovascular pathophysiologies, such as cardiomyocyte injury and cardiac hemodynamic stress, are strongly linked to the risk of death in patients with primarily non-cardiac disorders, such as pneumonia caused by SARS-CoV-2 or other causes.
The cardiac biomarker market is driven by the rising burden of cardiovascular diseases, technological advances in cardiac biomarkers, and growing research and development funding. For instance, according to a WHO article published in July 2021, an estimated 17.9 million people worldwide die from heart disease each year. This represents 31% of all deaths worldwide. This high prevalence of cardiovascular diseases is expected to drive the demand for early diagnosis and treatment, which may expand the scope of the market studied over the forecast period.
The technological advances in cardiac biomarkers are also anticipated to boost the market. For instance, in April 2021, Roche launched a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology, i.e., high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold-standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (cTnT-hs) and better manage heart failure (NT-proBNP).
Cardiac Biomarkers Market Trends
Troponin Expected to Show High Growth
Troponin tests are becoming a lucrative market due to their benefits in detecting myocardial infarction and congestive heart failure and their efficiency in diagnosing cardiovascular disorders in a timely and accurate manner compared to other tests. According to the study published in the National Library of Medicine by Saikrishna Patibandla in August 2021, cardiac troponins are the preferred blood test to evaluate patients suspected of having acute myocardial infarction and cardiac heart failure. This is because they are specific and sensitive biomarkers of cardiac ischemia. The levels of cardiac troponin in the blood can be detected using sensitive and highly sensitive assays.
The growing burden of cardiac diseases is anticipated to drive the demand for the troponin biomarkers segment. For instance, according to the study published in Frontiers in Cardiovascular Medicine in September 2021 (Bin Yu et al.), in the United States, a myocardial infraction occurs every 40 seconds, with an estimated annual incidence of 605,000 new cases and 200,000 recurrent cases and a prevalence of 3.0% among adults aged 20 years and older.
Many companies are focusing on developing breakthrough products for the treatment of cardiovascular diseases. For instance, in April 2021, Siemens Healthineers earned the CE Mark for its cardiac troponin point-of-care test. The Atellica VTLi Patient-Side Immunoassay Analyzer is a device that offers a point-of-care test to help diagnose heart attacks.
North America Dominates the Market
North America has a better healthcare infrastructure than other regions worldwide. The high burden of cardiovascular diseases in the region and the increased spending on the research and development of cardiovascular treatments are expected to drive the cardiac biomarkers market in the region during the forecast period.
According to the Centers for Disease Control and Prevention (CDC) (May 2022), COVID-19 patients with an underlying heart condition are likely to become severely ill. Additionally, according to the American College of Cardiology (ACC), people who have an underlying cardiovascular disease have a higher mortality rate when it comes to COVID-19 (10.5%) than people who have an underlying chronic respiratory disease (6.3%). Also, according to the Centers for Disease Control and Prevention (CDC)’s article titled “Heart Disease Facts,” updated in September 2020, heart disease is the leading cause of death in the United States. The same source also reports that about 805,000 Americans experience heart attacks every year.
There are initiatives that aim to create disease awareness, which is projected to support the market for cardiovascular devices in the North American region. For instance, in 2020, Mexico joined the HEARTS initiative to strengthen primary healthcare for cardiovascular diseases. Promoted by the Pan American Health Organization/World Health Organization (PAHO/WHO), the initiative aims to improve the prevention and control of hypertension at the primary care level.
Cardiac Biomarkers Market Competitor Analysis
The global players in the cardiac biomarkers market are Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. These companies are focused on achieving growth through the development of innovative products and new tests and improving the specificity of their tests.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cardiovascular Diseases
4.2.2 Technological Advancements in Cardiac Biomarkers
4.2.3 Growing Funding from Public and Private Organizations for R&D
4.3 Market Restraints
4.3.1 Stringent Regulatory Frameworks
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Type
5.1.1 Creatine Kinase
5.1.2 Troponins
5.1.3 Myoglobin
5.1.4 Ischemia Modified Albumin
5.1.5 Other Types
5.2 By Application
5.2.1 Congestive Heart Failure
5.2.2 Acute Coronary Syndrome
5.2.3 Myocardial Infarction
5.2.4 Atherosclerosis
5.2.5 Other Applications
5.3 By Location of Testing
5.3.1 Point-of-care Testing
5.3.2 Laboratory Testing
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson, and Company
6.1.3 BioMerieux
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Danaher Corporation
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Randox Laboratories
6.1.8 Siemens Healthineers
6.1.9 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS